Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CARISOPRODOL COMPOUND vs TRIHEXYPHENIDYL HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Carisoprodol is a centrally acting muscle relaxant that acts as a prodrug for meprobamate, a barbiturate-like compound with sedative and anxiolytic properties. Its mechanism is thought to involve GABA-A receptor modulation and depression of polysynaptic reflexes in the spinal cord and reticular formation. Aspirin provides analgesic and anti-inflammatory effects via irreversible inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. Codeine is an opioid agonist at mu-opioid receptors, producing analgesia by mimicking endogenous endorphins.
Trihexyphenidyl is an anticholinergic agent that competitively blocks central muscarinic receptors (primarily M1) in the striatum, restoring the balance between acetylcholine and dopamine in the basal ganglia. It also has mild peripheral anticholinergic effects.
Relief of discomfort associated with acute, painful musculoskeletal conditions,As an adjunct to rest, physical therapy, and other measures
Adjunctive therapy for all forms of Parkinson's disease,Treatment of drug-induced extrapyramidal symptoms (e.g., neuroleptic-induced parkinsonism, acute dystonia, akathisia)
1-2 tablets (carisoprodol 200 mg/aspirin 325 mg) orally 4 times daily.
1 mg orally initially, then increase by 2 mg every 3-5 days up to 6-10 mg daily in 3-4 divided doses; maximum 15 mg/day.
Carisoprodol has a terminal elimination half-life of approximately 1.5–2 hours; its active metabolite meprobamate has a half-life of 9–12 hours, which may lead to prolonged effects with chronic use.
10-17 hours; clinical context: steady-state concentrations achieved in 2-3 days.
Carisoprodol is metabolized by CYP2C19 to meprobamate (active metabolite). Aspirin is hydrolyzed by esterases in the liver and plasma to salicylic acid, which is further conjugated. Codeine is metabolized by CYP2D6 to morphine (active) and by CYP3A4 to norcodeine.
Primarily metabolized by hepatic microsomal enzymes, with CYP2D6 possibly involved. Elimination half-life is approximately 3–4 hours.
Carisoprodol is primarily metabolized in the liver, with about 50% excreted renally as unchanged drug and metabolites; the major metabolite meprobamate is also renally excreted. Fecal excretion is negligible (<2%).
Renal (primarily as unchanged drug and metabolites; <15% unchanged) and biliary/fecal (minor).
Carisoprodol is approximately 60% bound to plasma proteins, mainly albumin.
Minimal; approximately 10-20% bound to plasma proteins (albumin).
Volume of distribution is approximately 0.6–0.8 L/kg, indicating distribution into total body water.
Approximately 0.5-1.5 L/kg; indicates extensive tissue distribution.
Oral bioavailability is nearly complete (close to 100%) due to rapid and extensive absorption.
Oral: approximately 80-95% (first-pass metabolism minimal).
Contraindicated in severe renal impairment (Cr Cl <30 m L/min). No specific dose adjustment for mild-moderate impairment; use caution.
Cr Cl 10-50 m L/min: administer every 8-12 hours; Cr Cl <10 m L/min: consider alternative or reduce dose by 50%.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For moderate impairment, reduce dose or increase interval; specific guidelines not established.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: avoid use or use with extreme caution, reduce dose by 75%.
Not recommended for pediatric patients due to aspirin content and risk of Reye syndrome.
Children 2-12 years: initial 1 mg/day, increase by 1 mg every 3-5 days; maximum 6 mg/day in divided doses.
Initiate at lowest effective dose; monitor for CNS depression, falls, and aspirin-related bleeding. Avoid in patients ≥65 years due to risks of dizziness, sedation, and GI bleeding.
Start at 1 mg once or twice daily; increase slowly by 1 mg increments every 5-7 days; monitor for anticholinergic side effects.
None
Not applicable.
Risk of dependence, abuse, and withdrawal with carisoprodol and codeine,CYP2D6 ultrarapid metabolizers may have morphine toxicity from codeine,Reye's syndrome risk in children with viral illness (aspirin),GI bleeding risk with aspirin,Respiratory depression with codeine,Sedation and impaired motor function,Hepatic impairment,Renal impairment
May cause drowsiness, dizziness, or blurred vision; caution with driving or hazardous activities,Anticholinergic effects may be exacerbated in elderly patients, including confusion, constipation, urinary retention, and hyperthermia,Use cautiously in patients with glaucoma, prostatic hypertrophy, cardiac arrhythmias, or myasthenia gravis,Potential for abuse or dependence at high doses,May exacerbate tardive dyskinesia in patients on neuroleptics
Hypersensitivity to carisoprodol, meprobamate, aspirin, codeine, or any component,Porphyria,Acute intermittent porphyria,Children with viral illness (aspirin) due to Reye's syndrome risk,Breastfeeding (codeine),Severe renal or hepatic impairment,GI bleeding or peptic ulcer disease (aspirin),Concurrent use of MAOIs or within 14 days,Respiratory depression (codeine)
Hypersensitivity to trihexyphenidyl,Narrow-angle glaucoma,Obstructive gastrointestinal disorders (e.g., pyloric stenosis, paralytic ileus),Severe ulcerative colitis or toxic megacolon,Myasthenia gravis
Avoid alcohol and grapefruit juice. Alcohol increases CNS depression and risk of hepatotoxicity. Grapefruit juice may inhibit metabolism, leading to increased levels and toxicity.
No significant food interactions. However, avoid excessive alcohol consumption as it may exacerbate CNS depression and anticholinergic effects. Maintain adequate hydration to prevent constipation and dry mouth.
Carisoprodol is a pregnancy category C drug. Data from animal studies are insufficient or show adverse effects, but no adequate human studies exist. There is a potential risk of fetal harm if used during the first trimester due to possible neural tube defects based on limited reports. In the second and third trimesters, maternal use may cause neonatal withdrawal symptoms (e.g., irritability, feeding difficulties) and respiratory depression if used near term. Carisoprodol is not recommended during pregnancy unless benefit outweighs risk.
First trimester: Limited human data; animal studies show no consistent teratogenicity. Second and third trimesters: No known specific risks; use only if clearly needed.
Carisoprodol is excreted into human breast milk. The milk-to-plasma (M/P) ratio is approximately 2-4 based on small studies. An infant would receive a weight-adjusted dose of about 4-8% of the maternal dose, which may cause sedation, drowsiness, or irritability in the neonate. Breastfeeding is not recommended during carisoprodol use, especially in premature infants or those with hepatic impairment. If used, monitor infant for signs of CNS depression.
No data on M/P ratio; excreted in breast milk in unknown amounts. Caution recommended; avoid if possible.
No specific dosing adjustments for carisoprodol are established in pregnancy. However, due to increased plasma volume and altered hepatic metabolism in pregnancy, the drug's half-life may be reduced. Clinical monitoring for efficacy and maternal side effects (e.g., drowsiness, dizziness) is recommended. Use the lowest effective dose for the shortest duration. Consider avoidance of the compound formulation with aspirin or other NSAIDs, which have additional risks.
No established pharmacokinetic changes requiring dose adjustment; usual therapeutic dose maintained; monitor clinical response.
Carisoprodol is metabolized to meprobamate, a controlled substance with abuse potential; use cautiously in patients with history of substance abuse. Combination with other CNS depressants (e.g., alcohol, benzodiazepines) increases sedation risk. Limit use to 2-3 weeks due to lack of efficacy beyond that and risk of dependence. Avoid in patients with porphyria because carisoprodol may be porphyrinogenic.
Trihexyphenidyl is an anticholinergic agent used primarily for drug-induced parkinsonism and idiopathic Parkinson disease. It is less effective than levodopa but useful as adjunctive therapy. Onset of action is within 1 hour after oral administration; peak effect at 2-3 hours. Monitor for anticholinergic side effects: dry mouth, blurred vision, constipation, urinary retention, and cognitive impairment. Use with caution in elderly patients due to increased risk of confusion and falls. Abrupt withdrawal may precipitate parkinsonian crisis; taper gradually. Avoid in patients with narrow-angle glaucoma, myasthenia gravis, or gastrointestinal obstruction.
This medication may cause drowsiness, dizziness, or blurred vision; avoid driving or operating machinery until you know how it affects you.,Do not consume alcohol or other CNS depressants while taking this drug.,Take only as prescribed; do not increase dose or frequency. This drug has abuse potential.,Inform your doctor if you have a history of drug or alcohol abuse, seizures, or liver/kidney disease.,Do not use for longer than 2-3 weeks unless directed by your doctor.
Take exactly as prescribed; do not stop suddenly without consulting your doctor.,This medication may cause dry mouth, blurred vision, constipation, or difficulty urinating.,Avoid alcohol and other CNS depressants as they may increase drowsiness and dizziness.,Use caution when driving or operating machinery until you know how this drug affects you.,Report any eye pain, vision changes, or difficulty passing urine to your healthcare provider.,Do not chew sustained-release capsules; swallow whole.,If you miss a dose, take it as soon as you remember unless it is almost time for your next dose; do not double doses.
"The co-administration of pentobarbital, a barbiturate and potent CYP3A4 inducer, with carisoprodol, a prodrug that is metabolized to its active form, meprobamate, via CYP2C19, may lead to reduced plasma concentrations of meprobamate due to pentobarbital-induced upregulation of CYP2C19, potentially diminishing the sedative and muscle relaxant effects of carisoprodol. However, pentobarbital also acts as a central nervous system (CNS) depressant, and additive CNS depression can occur, increasing the risk of excessive sedation, respiratory depression, and impairment of psychomotor function. Clinical outcomes may include altered therapeutic efficacy of carisoprodol and heightened risk of CNS and respiratory adverse effects."
"Carisoprodol, a centrally acting skeletal muscle relaxant, is metabolized primarily by CYP2C19 to its active metabolite meprobamate. Isoniazid, a first-line antitubercular agent, is a known inhibitor of CYP2C19. When coadministered, isoniazid can decrease the metabolism of carisoprodol, leading to increased plasma concentrations of both carisoprodol and meprobamate. This elevation raises the risk of dose-related adverse effects such as sedation, dizziness, and respiratory depression, and may prolong the duration of muscle relaxant action."
"The combination of sulpiride, an atypical antipsychotic with dopamine D2 receptor antagonism and mild serotonin 5-HT4 agonist properties, and carisoprodol, a centrally acting muscle relaxant metabolized to meprobamate (a barbiturate-like sedative-hypnotic), can result in additive central nervous system (CNS) depression, including sedation, dizziness, and psychomotor impairment. Additionally, both drugs may lower the seizure threshold, increasing the risk of seizures. Sulpiride can also prolong the QT interval, and carisoprodol's sedative effects may mask or exacerbate this cardiotoxicity, potentially leading to ventricular arrhythmias such as torsade de pointes."
"Trihexyphenidyl, an anticholinergic agent, may potentiate the tachycardic effects of nabilone, a synthetic cannabinoid, due to additive inhibition of parasympathetic tone. This interaction can lead to clinically significant sinus tachycardia, palpitations, and potentially exacerbate underlying cardiovascular conditions such as coronary artery disease or arrhythmias."
"The concurrent use of trihexyphenidyl, an anticholinergic agent, with meperidine, an opioid analgesic, increases the risk of severe adverse effects such as central nervous system depression, respiratory depression, and anticholinergic toxicity (e.g., delirium, hyperthermia, and urinary retention). This additive pharmacodynamic interaction occurs due to combined anticholinergic and opioid properties, potentially leading to life-threatening outcomes, especially in elderly or debilitated patients. Clinicians should consider alternative therapies or closely monitor for signs of excessive sedation, respiratory compromise, and anticholinergic crisis."
"Donepezil, a cholinesterase inhibitor used in Alzheimer's disease, increases acetylcholine levels in the central nervous system. Trihexyphenidyl, an anticholinergic agent for Parkinson's disease, blocks muscarinic acetylcholine receptors. Concurrent use results in functional antagonism, where trihexyphenidyl's anticholinergic effects diminish the efficacy of donepezil, potentially worsening cognitive function in Alzheimer's patients."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CARISOPRODOL COMPOUND vs TRIHEXYPHENIDYL HYDROCHLORIDE, answered by our medical review team.
CARISOPRODOL COMPOUND is a Skeletal Muscle Relaxant that works by Carisoprodol is a centrally acting muscle relaxant that acts as a prodrug for meprobamate, a barbiturate-like compound with sedative and anxiolytic properties. Its mechanism is thought to involve GABA-A receptor modulation and depression of polysynaptic reflexes in the spinal cord and reticular formation. Aspirin provides analgesic and anti-inflammatory effects via irreversible inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. Codeine is an opioid agonist at mu-opioid receptors, producing analgesia by mimicking endogenous endorphins.. TRIHEXYPHENIDYL HYDROCHLORIDE is a Anticholinergic Antiparkinsonian that works by Trihexyphenidyl is an anticholinergic agent that competitively blocks central muscarinic receptors (primarily M1) in the striatum, restoring the balance between acetylcholine and dopamine in the basal ganglia. It also has mild peripheral anticholinergic effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CARISOPRODOL COMPOUND and TRIHEXYPHENIDYL HYDROCHLORIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CARISOPRODOL COMPOUND is: 1-2 tablets (carisoprodol 200 mg/aspirin 325 mg) orally 4 times daily.. The standard adult dose of TRIHEXYPHENIDYL HYDROCHLORIDE is: 1 mg orally initially, then increase by 2 mg every 3-5 days up to 6-10 mg daily in 3-4 divided doses; maximum 15 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CARISOPRODOL COMPOUND and TRIHEXYPHENIDYL HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CARISOPRODOL COMPOUND is classified as Category A/B. Carisoprodol is a pregnancy category C drug. Data from animal studies are insufficient or show adverse effects, but no adequate human studies exist. There is a potential risk of fe. TRIHEXYPHENIDYL HYDROCHLORIDE is classified as Category C. First trimester: Limited human data; animal studies show no consistent teratogenicity. Second and third trimesters: No known specific risks; use only if clearly needed.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.